MicroRNAs as regulators of metabolic disease: Pathophysiologic significance and emerging role as biomarkers and therapeutics

International Journal of Obesity

Volumn 40, Issue 1, 2016, Pages 88-101

  Deiuliis, J A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; BIOLOGICAL MARKER; INSULIN; MICRORNA; MICRORNA 126; MICRORNA 130; MICRORNA 132; MICRORNA 143; MICRORNA 145; MICRORNA 17; MICRORNA 200; MICRORNA 200A; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 29; MICRORNA 34A; MICRORNA 375; MICRORNA 92; UNCLASSIFIED DRUG;

ADIPOGENESIS; FOOD INTAKE; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; METABOLIC DISORDER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; ANIMAL; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DISEASE MODEL; GENETICS; METABOLIC SYNDROME X; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; PREVALENCE; SIGNAL TRANSDUCTION; TRENDS; UNITED STATES;

ADIPOGENESIS; ANIMALS; BIOMARKERS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; MICE; MICRORNAS; MOLECULAR TARGETED THERAPY; OBESITY; PREVALENCE; SIGNAL TRANSDUCTION; UNITED STATES;

EID: 84953348089     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2015.170     Document Type: Review

References (145)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311: 806-814.
2. Fullston T, Ohlsson Teague EM, Palmer NO, DeBlasio MJ, Mitchell M, Corbett M et al. Paternal obesity initiates metabolic disturbances in two generations of mice with incomplete penetrance to the F2 generation and alters the transcriptional profile of testis and sperm microRNA content. FASEB J 2013; 27: 4226-4243.
3. Gonzalez-Bulnes A, Astiz S, Ovilo C, Lopez-Bote CJ, Sanchez-Sanchez R, Perez-Solana ML et al. Early-postnatal changes in adiposity and lipids profile by transgenerational developmental programming in swine with obesity/leptin resistance. J Endocrinol 2014; 223: M17-M29.
4. Multhaup ML, Seldin MM, Jaffe AE, Lei X, Kirchner H, Mondal P et al. Mousehuman experimental epigenetic analysis unmasks dietary targets and genetic liability for diabetic phenotypes. Cell Metab 2015; 21: 138-149.
5. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
6. Nagareddy PR, Kraakman M, Masters SL, Stirzaker RA, Gorman DJ, Grant RW et al. Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab 2014; 19: 821-835.
7. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factoralpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993; 268: 26055-26058.
8. Vatner DF, Majumdar SK, Kumashiro N, Petersen MC, Rahimi Y, Gattu AK et al. Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids. Proc Natl Acad Sci USA 2015; 112: 1143-1148.
9. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-190.
10. Ferreira DM, Simao AL, Rodrigues CM, Castro RE. Revisiting the Metabolic Syndrome and Paving the Way for microRNAs in Non-Alcoholic Fatty Liver Disease. FEBS J 2014; 281: 2503-2524.
11. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801.
12. Thaler JP, Yi C-X, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 2012; 122: 153-162.
13. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 1996; 271: 665-668.
14. De Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 2004; 279: 17070-17078.
15. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
16. Chawla A, Nguyen KD, Goh YPS. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol 2011; 11: 738-749.
17. Zhuang G, Meng C, Guo X, Cheruku PS, Shi L, Xu H et al. A Novel Regulator of Macrophage Activation: miR-223 in Obesity Associated Adipose Tissue Inflammation. Circulation 2012; 125: 2892-2903.
18. Carolan E, Hogan AE, Corrigan M, Gaotswe G, O'Connell J, Foley N et al. The impact of childhood obesity on inflammation, innate immune cell frequency and metabolic microRNA expression. J Clin Endocrinol Metab 2013; 99: E474-E478.
19. Olivo-Marston SE, Hursting SD, Perkins SN, Schetter A, Khan M, Croce C et al. Effects of calorie restriction and diet-induced obesity on murine colon carcinogenesis, growth and inflammatory factors, and microRNA expression. PLoS One 2014; 9: e94765.
20. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75: 855-862.
21. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-854.
22. Lee C-T, Risom T, Strauss WM. Evolutionary conservation of microRNA regulatory circuits: an examination of microRNA gene complexity and conserved microRNA-target interactions through metazoan phylogeny. DNA Cell Biol 2007; 26: 209-218.
23. Friedman RC, KK-H Farh, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
24. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 2010; 11: 252-263.
25. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13: 239-250.
26. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136: 642-655.
27. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
28. Martin HC, Wani S, Steptoe AL, Krishnan K, Nones K, Nourbakhsh E et al. Imperfect centered miRNA binding sites are common and can mediate repression of target mRNAs. Genome Biol 2014; 15: R51.
29. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11: 228-234.
30. Gott JM, Emeson RB. Functions and mechanisms of RNA editing. Annu Rev Genet 2000; 34: 499-531.
31. Yang W, Chendrimada TP, Wang Q, Higuchi M, Seeburg PH, Shiekhattar R et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol 2006; 13: 13-21.
32. Luciano DJ, Mirsky H, Vendetti NJ, Maas S. RNA editing of a miRNA precursor. RNA 2004; 10: 1174-1177.
33. Hundley HA, Bass BL. ADAR editing in double-stranded UTRs and other noncoding RNA sequences. Trends Biochem Sci 2010; 35: 377-383.
34. Athanasiadis A, Rich A, Maas S. Widespread A-to-I RNA editing of Alu-containing mRNAs in the human transcriptome. PLoS Biol 2004; 2: e391.
35. Yang L, Huang P, Li F, Zhao L, Zhang Y, Li S et al. c-Jun amino-terminal kinase-1 mediates glucose-responsive upregulation of the RNA editing enzyme ADAR2 in pancreatic beta-cells. PLoS One 2012; 7: e48611.
36. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012; 3: 1.
37. Kloting N, Berthold S, Kovacs P, Schon MR, Fasshauer M, Ruschke K et al. MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS One 2009; 4: e4699.
38. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677-684.
39. Heneghan HM, Miller N, McAnena OJ, O'Brien T, Kerin MJ. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J Clin Endocrinol Metab 2011; 96: E846-E850.
40. Hulsmans M, Holvoet P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. Cardiovasc Res 2013; 100: 7-18.
41. Steiner DF, Thomas MF, Hu JK, Yang Z, Babiarz JE, Allen CDC et al. MicroRNA-29 regulates T-box transcription factors and interferon-production in helper T cells. Immunity 2011; 35: 169-181.
42. Li H, Li T, Wang S, Wei J, Fan J, Li J et al. miR-17-5p and miR-106a are involved in the balance between osteogenic and adipogenic differentiation of adiposederived mesenchymal stem cells. Stem Cell Res 2013; 10: 313-324.
43. Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009; 460: 705-710.
44. Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004; 279: 52361-52365.
45. Kajimoto K, Naraba H, Iwai N. MicroRNA and 3T3-L1 pre-adipocyte differentiation. RNA 2006; 12: 1626-1632.
46. Takanabe R, Ono K, Abe Y, Takaya T, Horie T, Wada H et al. Up-regulated expression of microRNA-143 in association with obesity in adipose tissue of mice fed high-fat diet. Biochem Biophys Res Commun 2008; 376: 728-732.
47. Xie H, Lim B, Lodish HF. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009; 58: 1050-1057.
48. Jordan SD, Kruger M, Willmes DM, Redemann N, Wunderlich FT, Bronneke HS et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 2011; 13: 434-446.
49. Lorente-Cebrián S, Mejhert N, Kulyté A, Laurencikiene J, Åström G, Hedén P et al. MicroRNAs regulate human adipocyte lipolysis: effects of miR-145 are linked to TNF-. PLoS One 2014; 9: e86800.
50. Lin Y-Y, Chou C-F, Giovarelli M, Briata P, Gherzi R, Chen C-Y. KSRP and microRNA 145 are negative regulators of lipolysis in white adipose tissue. Mol Cell Biol 2014; 34: 2339-2349.
51. Wen F, Yang Y, Jin D, Sun J, Yu X, Yang Z. MiRNA-145 is involved in the development of resistin-induced insulin resistance in HepG2 cells. Biochem Biophys Res Commun 2014; 445: 517-523.
52. Lee EK, Lee MJ, Abdelmohsen K, Kim W, Kim MM, Srikantan S et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferatoractivated receptor gamma expression. Mol Cell Biol 2011; 31: 626-638.
53. Ortega FJ, Mercader JM, Catalán V, Moreno-Navarrete JM, Pueyo N, Sabater M et al. Targeting the circulating microRNA signature of obesity. Clin Chem 2013; 59: 781-792.
54. Prats-Puig A, Ortega FJ, Mercader JM, Moreno-Navarrete JM, Moreno M, Bonet N et al. Changes in circulating microRNAs are associated with childhood obesity. J Clin Endocrinol Metab 2013; 98: E1655-E1660.
55. Pan S, Yang X, Jia Y, Li R, Zhao R. Microvesicle-shuttled miR-130b reduces fat deposition in recipient primary cultured porcine adipocytes by inhibiting PPAR-g expression. J Cell Physiol 2014; 229: 631-639.
56. Pan S, Zheng Y, Zhao R, Yang X. MicroRNA-130b and microRNA-374b mediate the effect of maternal dietary protein on offspring lipid metabolism in Meishan pigs. Br J Nutr 2013; 109: 1731-1738.
57. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000; 408: 86-89.
58. Zhu H, Shyh-Chang N, Segre A V, Shinoda G, Shah SP, Einhorn WS et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 2011; 147: 81-94.
59. Frost RJ, Olson EN. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci USA 2011; 108: 21075-21080.
60. Jiang LQ, Franck N, Egan B, Sjogren RJ, Katayama M, Duque-Guimaraes D et al. Autocrine role of interleukin-13 on skeletal muscle glucose metabolism in type 2 diabetic patients involves microRNA let-7. Am J Physiol Endocrinol Metab 2013; 305: E1359-E1366.
61. McCann SE, Liu S, Wang D, Shen J, Hu Q, Hong CC et al. Reduction of dietary glycaemic load modifies the expression of microRNA potentially associated with energy balance and cancer pathways in pre-menopausal women. Br J Nutr 2013; 109: 585-592.
62. Santovito D, De Nardis V, Marcantonio P, Mandolini C, Paganelli C, Vitale E et al. Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in Diabetes: effect of glycemic control. J Clin Endocrinol Metab 2014; 99: E1681-E1685.
63. Nardelli C, Iaffaldano L, Ferrigno M, Labruna G, Maruotti GM, Quaglia F et al. Characterization and predicted role of the microRNA expression profile in amnion from obese pregnant women. Int J Obes (Lond) 2014; 38: 466-469.
64. Sun T, Fu M, Bookout AL, Kliewer SA, Mangelsdorf DJ. MicroRNA let-7 regulates 3T3-L1 adipogenesis. Mol Endocrinol 2009; 23: 925-931.
65. Wei J, Li H, Wang S, Li T, Fan J, Liang X et al. let-7 enhances osteogenesis and bone formation while repressing adipogenesis of human stromal/mesenchymal stem cells by regulating HMGA2. Stem Cells Dev 2014; 23: 1452-1463.
66. Herrera BM, Lockstone HE, Taylor JM, Ria M, Barrett A, Collins S et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010; 53: 1099-1109.
67. Chartoumpekis DV, Zaravinos A, Ziros PG, Iskrenova RP, Psyrogiannis AI, Kyriazopoulou VE et al. Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice. PLoS One 2012; 7: e34872.
68. Shi Z, Zhao C, Guo X, Ding H, Cui Y, Shen R et al. Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ERalpha expression in estrogen-induced insulin resistance. Endocrinology 2014; 155: 1982-1990.
69. Ortega FJ, Mercader JM, Moreno-Navarrete JM, Rovira O, Guerra E, Esteve E et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care 2014; 37: 1375-1383.
70. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13: 423-433.
71. Lustig Y, Barhod E, Ashwal-Fluss R, Gordin R, Shomron N, Baruch-Umansky K et al. RNA-binding protein PTB and microRNA-221 coregulate AdipoR1 translation and adiponectin signaling. Diabetes 2014; 63: 433-445.
72. Chou W-W, Wang Y-T, Liao Y-C, Chuang S-C, Wang S-N, Juo S-HH. Decreased microRNA-221 is associated with high levels of TNF-in human adipose tissue-derived mesenchymal stem cells from obese woman. Cell Physiol Biochem 2013; 32: 127-137.
73. Meerson A, Traurig M, Ossowski V, Fleming JM, Mullins M, Baier LJ. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-alpha. Diabetologia 2013; 56: 1971-1979.
74. Wang Y-T, Tsai P-C, Liao Y-C, Hsu C-Y, Juo S-HH. Circulating microRNAs have a sex-specific association with metabolic syndrome. J Biomed Sci 2013; 20: 72.
75. Benoit C, Ould-Hamouda H, Crepin D, Gertler A, Amar L, Taouis M. Early leptin blockade predisposes fat-fed rats to overweight and modifies hypothalamic microRNAs. J Endocrinol 2013; 218: 35-47.
76. Crepin D, Benomar Y, Riffault L, Amine H, Gertler A, Taouis M. The overexpression of miR-200a in the hypothalamus of ob/ob mice is linked to leptin and insulin signaling impairment. Mol Cell Endocrinol 2014; 384: 1-11.
77. Dou L, Zhao T, Wang L, Huang X, Jiao J, Gao D et al. miR-200 s contribute to interleukin-6 (IL-6)-induced insulin resistance in hepatocytes. J Biol Chem 2013; 288: 22596-22606.
78. Kennell JA, Gerin I, MacDougald OA, Cadigan KM. The microRNA miR-8 is a conserved negative regulator of Wnt signaling. Proc Natl Acad Sci USA 2008; 105: 15417-15422.
79. Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D, McInnes IB et al. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol 2012; 189: 3795-3799.
80. Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG. MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat Immunol 2010; 11: 799-805.
81. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 107: 810-817.
82. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-5008.
83. Ismail N, Wang Y, Dakhlallah D, Moldovan L, Agarwal K, Batte K et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood 2013; 121: 984-995.
84. Foley NH, O'Neill LA. miR-107: a toll-like receptor-regulated miRNA dysregulated in obesity and type II diabetes. J Leukoc Biol 2012; 92: 521-527.
85. Hulsmans M, Van Dooren E, Mathieu C, Holvoet P. Decrease of miR-146b-5p in monocytes during obesity is associated with loss of the anti-inflammatory but not insulin signaling action of adiponectin. PLoS One 2012; 7: e32794.
86. Du F, Yu F, Wang Y, Hui Y, Carnevale K, Fu M et al. MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2014; 34: 759-767.
87. Liu S, Yang Y, Wu J. TNF-induced up-regulation of miR-155 inhibits adipogenesis by down-regulating early adipogenic transcription factors. Biochem Biophys Res Commun 2011; 414: 618-624.
88. Vickers KC, Landstreet SR, Levin MG, Shoucri BM, Toth CL, Taylor RC et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci USA 2014; 111: 14518-14523.
89. He A, Zhu L, Gupta N, Chang Y, Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 2007; 21: 2785-2794.
90. Kurtz CL, Peck BC, Fannin EE, Beysen C, Miao J, Landstreet SR et al. microRNA-29 fine-tunes the expression of key FOXA2-activated lipid metabolism genes and is dysregulated in animal models of insulin resistance and diabetes. Diabetes 2014; 63: 3141-3148.
91. Nicholas LM, Rattanatray L, MacLaughlin SM, Ozanne SE, Kleemann DO, Walker SK et al. Differential effects of maternal obesity and weight loss in the periconceptional period on the epigenetic regulation of hepatic insulin-signaling pathways in the offspring. FASEB J 2013; 27: 3786-3796.
92. Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol 2011; 48: 61-69.
93. Peng H, Zhong M, Zhao W, Wang C, Zhang J, Liu X et al. Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients. PLoS One 2013; 8: e82607.
94. Plaisance V, Waeber G, Regazzi R, Abderrahmani A. Role of microRNAs in islet beta-cell compensation and failure during diabetes. J Diabetes Res 2014; 2014: 618-652.
95. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004; 432: 226-230.
96. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P et al. miR-375 maintains normal pancreatic alpha-and beta-cell mass. Proc Natl Acad Sci USA 2009; 106: 5813-5818.
97. Tattikota SG, Rathjen T, McAnulty SJ, Wessels H-H, Akerman I, van de Bunt M et al. Argonaute2 mediates compensatory expansion of the pancreatic cell. Cell Metab 2014; 19: 122-134.
98. Dumortier O, Hinault C, Gautier N, Patouraux S, Casamento V, Van Obberghen E. Maternal protein restriction leads to pancreatic failure in offspring: role of misexpressed microRNA-375. Diabetes 2014; 63: 3416-3427.
99. Higuchi C, Nakatsuka A, Eguchi J, Teshigawara S, Kanzaki M, Katayama A et al. Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes. Metabolism 2015; 64: 489-497.
100. Ling H-Y, Wen G-B, Feng S-D, Tuo Q-H, Ou H-S, Yao CH et al. MicroRNA-375 promotes 3T3-L1 adipocyte differentiation through modulation of extracellular signal-regulated kinase signalling. Clin Exp Pharmacol Physiol 2011; 38: 239-246.
101. Gallagher IJ, Scheele C, Keller P, Nielsen AR, Remenyi J, Fischer CP et al. Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med 2010; 2: 9.
102. Labialle S, Cavaillé J. Do repeated arrays of regulatory small-RNA genes elicit genomic imprinting: Concurrent emergence of large clusters of small noncoding RNAs and genomic imprinting at four evolutionarily distinct eutherian chromosomal loci. Bioessays 2011; 33: 565-573.
103. Kameswaran V, Bramswig NC, McKenna LB, Penn M, Schug J, Hand NJ et al. Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. Cell Metab 2014; 19: 135-145.
104. Benatti RO, Melo AM, Borges FO, Ignacio-Souza LM, Simino LA, Milanski M et al. Maternal high-fat diet consumption modulates hepatic lipid metabolism and microRNA-122 (miR-122) and microRNA-370 (miR-370) expression in offspring. Br J Nutr 2014; 111: 2112-2122.
105. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010; 56: 1733-1741.
106. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
107. Mestdagh P, Hartmann N, Baeriswyl L, Andreasen D, Bernard N, Chen C et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods 2014; 11: 809-815.
108. Pescador N, Perez-Barba M, Ibarra JM, Corbaton A, Martinez-Larrad MT, Serrano-Rios M. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PLoS One 2013; 8: e77251.
109. Ray P, Le Manach Y, Riou B, Houle TT. Statistical evaluation of a biomarker. Anesthesiology 2010; 112: 1023-1040.
110. Van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res 2012; 110: 496-507.
111. Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896-899.
112. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478: 404-407.
113. Distel E, Barrett TJ, Chung K, Girgis NM, Parathath S, Essau CC et al. miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice. Circ Res 2014; 115: 759-769.
114. Goedeke L, Salerno A, Ramírez CM, Guo L, Allen RM, Yin X et al. Long-term therapeutic silencing of miR-33 increases circulating triglyceride levels and hepatic lipid accumulation in mice. EMBO Mol Med 2014; 6: 1133-1141.
115. Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011; 43: 371-378.
116. Morin RD, O'Connor MD, Griffith M, Kuchenbauer F, Delaney A, Prabhu A-L et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res 2008; 18: 610-621.
117. Baran-Gale J, Fannin EE, Kurtz CL, Sethupathy P. Beta cell 5'-shifted isomiRs are candidate regulatory hubs in type 2 diabetes. PLoS One 2013; 8: e73240.
118. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by 'walking' the genes of three genomes. J Biomed Inform 2011; 44: 839-847.
119. Hsu S-D, Tseng Y-T, Shrestha S, Lin Y-L, Khaleel A, Chou C-H et al. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res 2014 42: D78-D85.
120. Russo F, Di Bella S, Nigita G, Macca V, Laganà A, Giugno R et al. miRandola: extracellular circulating microRNAs database. PLoS One 2012; 7: e47786.
121. Park CY, Jeker LT, Carver-Moore K, Oh A, Liu HJ, Cameron R et al. A resource for the conditional ablation of microRNAs in the mouse. Cell Rep 2012; 1: 385-391.
122. Nesca V, Guay C, Jacovetti C, Menoud V, Peyot ML, Laybutt DR et al. Identification of particular groups of microRNAs that positively or negatively impact on beta cell function in obese models of type 2 diabetes. Diabetologia 2013; 56: 2203-2212.
123. Viesti A, Collares R, Salgado W, Pretti da Cunha Tirapelli D, dos Santos JS. The expression of LEP, LEPR, IGF1 and IL10 in obesity and the relationship with microRNAs. PLoS One 2014; 9: e93512.
124. Kim C, Lee H, Cho YM, Kwon O-J, Kim W, Lee EK. TNF-induced miR-130 resulted in adipocyte dysfunction during obesity-related inflammation. FEBS Lett 2013; 587: 3853-3858.
125. Arner E, Mejhert N, Kulyte A, Balwierz PJ, Pachkov M, Cormont M et al. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes 2012; 61: 1986-1993.
126. Yu J, Kong X, Liu J, Lv Y, Sheng Y, Lv S et al. Expression profiling of PPAR-regulated microRNAs in human subcutaneous and visceral adipogenesis in both genders. Endocrinology 2014; 155: 2155-2165.
127. Kulyté A, Lorente-Cebrián S, Gao H, Mejhert N, Agustsson T, Arner P et al. MicroRNA profiling links miR-378 to enhanced adipocyte lipolysis in human cancer cachexia. Am J Physiol Endocrinol Metab 2014; 306: E267-E274.
128. Xie H, Lim B, Lodish HF. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009; 58: 1050-1057.
129. Chen H, Wang S, Chen L, Chen Y, Wu M, Zhang Y et al. MicroRNA-344 inhibits 3T3-L1 cell differentiation via targeting GSK3 of Wnt/-catenin signaling pathway. FEBS Lett 2014; 588: 429-435.
130. Fu T, Seok S, Choi S, Huang Z, Suino-Powell K, Xu HE et al. MicroRNA 34a inhibits beige and brown fat formation in obesity in part by suppressing adipocyte fibroblast growth factor 21 signaling and SIRT1 function. Mol Cell Biol 2014; 34: 4130-4142.
131. Li H, Chen X, Guan L, Qi Q, Shu G, Jiang Q et al. MiRNA-181a regulates adipogenesis by targeting tumor necrosis factor-(TNF-) in the porcine model. PLoS One 2013; 8: e71568.
132. Ling HY, Hu B, Hu XB, Zhong J, Feng SD, Qin L et al. MiRNA-21 reverses high glucose and high insulin induced insulin resistance in 3T3-L1 adipocytes through targeting phosphatase and tensin homologue. Exp Clin Endocrinol Diabetes 2012; 120: 553-559.
133. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011; 474: 649-653.
134. Xiao F, Yu J, Liu B, Guo Y, Li K, Deng J et al. A novel function of microRNA 130a-3p in hepatic insulin sensitivity and liver steatosis. Diabetes 2014; 63: 2631-2642.
135. Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009; 49: 1176-1184.
136. Kornfeld JW, Baitzel C, Konner AC, Nicholls HT, Vogt MC, Herrmanns K et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature 2013; 494: 111-115.
137. Zhou B, Li C, Qi W, Zhang Y, Zhang F, Wu JX et al. Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia 2012; 55: 2032-2043.
138. Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res 2010; 51: 1513-1523.
139. Liang T, Liu C, Ye Z. Deep sequencing of small RNA repertoires in mice reveals metabolic disorders-associated hepatic miRNAs. PLoS One 2013; 8: e80774.
140. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98.
141. Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 2014; 34: e302-e307.
142. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011; 121: 2921-2931.
143. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328: 1570-1573.
144. Lee H, Jee Y, Hong K, Hwang GS, Chun K-HH. MicroRNA-494, upregulated by tumor necrosis factor-alpha, desensitizes insulin effect in C2C12 muscle cells. PLoS One 2013; 8: e83471.
145. Zhang Y, Yang L, Gao YF, Fan ZM, Cai XY, Liu MY et al. MicroRNA-106b induces mitochondrial dysfunction and insulin resistance in C2C12 myotubes by targeting mitofusin-2. Mol Cell Endocrinol 2013; 381: 230-240.